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Atherosclerosis is an inflammatory process of the vascular wall characterized by the infil-
tration of lipids and inflammatory cells. Oxidative modifications of infiltrating low-density
lipoproteins and induction of oxidative stress play a major role in lipid retention in the vas-
cular wall, uptake by macrophages and generation of foam cells, a hallmark of this disorder.
The vasculature has a plethora of protective resources against oxidation and inflammation,
many of them regulated by the Nrf2 transcription factor. Heme oxygenase-1 (HO-1) is a
Nrf2-regulated gene that plays a critical role in the prevention of vascular inflammation. It
is the inducible isoform of HO, responsible for the oxidative cleavage of heme groups lead-
ing to the generation of biliverdin, carbon monoxide, and release of ferrous iron. HO-1 has
important antioxidant, antiinflammatory, antiapoptotic, antiproliferative, and immunomodu-
latory effects in vascular cells, most of which play a significant role in the protection against
atherogenesis. HO-1 may also be an important feature in macrophage differentiation and
polarization to certain subtypes.The biological effects of HO-1 are largely attributable to its
enzymatic activity, which can be conceived as a system with three arms of action, corre-
sponding to its three enzymatic byproducts. HO-1 mediated vascular protection may be due
to a combination of systemic and vascular local effects. It is usually expressed at low levels
but can be highly upregulated in the presence of several proatherogenic stimuli. The HO-1
system is amenable for use in the development of new therapies, some of them currently
under experimental and clinical trials. Interestingly, in contrast to the HO-1 antiatherogenic
actions, the expression of its transcriptional regulator Nrf2 leads to proatherogenic effects
instead. This suggests that a potential intervention on HO-1 or its byproducts may need
to take into account any potential alteration in the status of Nrf2 activation. This article
reviews the available evidence that supports the antiatherogenic role of HO-1 as well as
the potential pathways and mechanisms mediating vascular protection.
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HEME OXYGENASE-1 AND VASCULAR INFLAMMATION:
IMPORTANCE OF BASAL LEVELS
Heme oxygenase (HO) is a rate-limiting enzyme in the catab-
olism of heme. In association with cytochrome P450 reductase
and in the presence of NADPH and three molecules of molec-
ular oxygen (O2) per heme molecule, it catalyzes the oxidative
cleavage of heme (Fe-protoporphyrin-IX) to render equimolar
amounts of biliverdin, ferrous iron (Fe2+), and carbon monoxide
(CO; Maines, 1997; Figure 1). Biliverdin can then be converted
to bilirubin by the cytosolic enzyme biliverdin reductase (BVR).
There are three HO isoforms (HO-1, HO-2, HO-3) that have been
described (Siow et al., 1999), although HO-3 may be a pseudo-
gene derived from HO-2 transcripts (Hayashi et al., 2004). While
HO-2 is constitutively expressed, HO-1 is normally expressed at
low levels in most tissues but it is highly inducible by a variety
of stimuli. Indeed, HO-1 may be among the most critical cyto-
protective mechanisms that are activated during times of cellular
stress such as inflammation, ischemia, hypoxia, hyperoxia, hyper-
thermia, or radiation (Choi and Alam, 1996). It is thought to play
a key role in maintaining antioxidant/oxidant homeostasis and
in the prevention against vascular injury (Abraham and Kappas,
2008).
Cumulative evidence has shown that expression of HO-1 in the
vasculature exerts protective effects against vascular inflammatory
processes, thanks to its antioxidant, antiinflammatory, antiapop-
totic, and possibly immunomodulatory properties. Thus, HO-1
antioxidant protection is particularly evident against the vascu-
lar inflammation occurring in models of antigen-independent
ischemia reperfusion injury (IRI), where the reintroduction of
oxygen after a period of ischemia and generation of reactive oxygen
species (ROS) constitutes the central pathogenic event. Pharma-
cological competitive inhibitors of HO activity such as the heme
analogs SnPPIX or ZnPPIX (Kato et al., 2001) or decreased HO-1
expression in genetically engineered HO-1+/− mice lead to sig-
nificant worsening of IRI outcomes (Tsuchihashi et al., 2006).
On the other hand, HO-1 overexpression by either pharmaco-
logical means or via genetic engineering has been reported to
exert potent cytoprotective effects in hepatic IRI transplant mod-
els, with profoundly diminished proinflammatory and apoptotic
responses (Amersi et al., 1999; Kato et al., 2001; Coito et al., 2002).
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FIGURE 1 | Heme oxygenase enzymatic activity. HO enzymatic leads to
the generation of biliverdin, release of carbon monoxide (CO) and Fe2+.
Biliverdin is transformed into bilirubin by the biliverdin reductase (BVR)
enzyme. Fe2+ can be bound by the iron storage protein ferritin.
Of importance, basal HO-1 levels, rather than the degree of HO-1
upregulation, appear to be crucial in the antioxidant cytoprotec-
tion as indicated by data obtained from HO-1+/− and HO-1+/+
mice subjected to partial liver warm ischemia for 90 min followed
by 6 h of reperfusion (Tsuchihashi et al., 2006; Figure 2). Liver
IRI injury is characterized by hepatocellular damage consisting in
neutrophil infiltration, sinusoidal congestion, hepatocyte apop-
tosis/necrosis, and ballooning degeneration as well as impaired
hepatocyte function that can be determined by elevation of serum
transaminases such as the serum glutamic-oxaloacetic transam-
inase (sGOT) and the glutamic-pyruvic transaminase (sGPT).
Treatment with CoPP (Cobalt Protoporhyrin), a synthetic ana-
log of heme that induces HO-1 without competing for its cat-
alytic site, led to upregulation in both basal (Figure 2A) and
post-IRI HO-1 mRNA levels (Figure 2B) that led to decreased
IRI overall, evidenced by decreased post-IRI serum transami-
nases. Interestingly, both basal (Figure 2C) and post-IRI HO-1
mRNA levels (Tsuchihashi et al., 2006) correlated negatively with
sGPT levels but the degree of correlation was bigger with the
basal (R2= 0.87, p= 0.0002) than with the post-IRI HO-1 lev-
els (R2= 0.55, p= 0.0002). In addition, sGPT levels correlated
positively with the degree of HO-1 fold induction (Figure 2D),
suggesting that the basal HO-1 levels (Figure 2A) may be more
important than the degree of upregulation. However, this could
also be due to the HO-1 behavior as a stress-responsive gene
since it can be rapidly and highly upregulated by a large variety
of acute stressors. Therefore, the degree of HO-1 fold induction
might reflect the level of stress induced in the liver by the ischemia
reperfusion rather than an ability to protect against the injury.
Heme oxygenase-1 antiinflammatory properties are clearly evi-
dent in models of organ transplantation, not only as a consequence
of the protection against IRI but also by protecting against antigen-
dependent immune responses. Thus, pharmacological inhibition
(Hancock et al., 1998) or decreased HO-1 expression in mouse
cardiac allografts lead to accelerated acute rejection, in paral-
lel with similar results in mouse to rat xenografts (Soares et al.,
1998). In addition, HO-1 overexpression in the cardiac allograft
results in prolongation of the graft survival, which is much more
dramatically improved when HO-1 is overexpressed in the recip-
ient host rather than the donor organ (Araujo et al., 2003). It
is possible then that HO-1 antiinflammatory properties involve
specific immunomodulatory actions that could affect antigen pre-
sentation and/or shifting of the type of cellular immune response
(Araujo et al., 2003; Chauveau et al., 2005). Interestingly, in a
mouse model of heterotopic cardiac allograft transplantation,
where C57BL/6J hearts were transplanted into BALB/cByJ recip-
ients, hearts from HO-1± mice, with HO-1 mRNA levels ∼60%
of wild-type (WT) controls displayed shorter survival, despite a
much larger degree of HO-1 upregulation after the transplant
(unpublished), suggesting that basal HO-1 could be key in anti-
inflammatory protection. However, the different degree of HO-1
fold induction in HO-1± mice could also reflect here, as it does in
the case of the IRI, a greater level of stress induced in the trans-
planted hearts by various inflammatory stressors rather than a
different ability to protect against the rejection response.
This notion was further confirmed in human aor-
tic endothelial cells (HAECs) from 149 individual donors
treated with oxidized 1-palmitoyl-2-arachidonyl-sn-glycero-3-
phosphorylcholine (oxPAPC) as mentioned in more details below
(Romanoski et al., 2011; Figure 3). In brief, baseline HO-1 mRNA
levels, as judged by HAECs treated with media alone, exhibited
a significant variation among different donors whereas treatment
with oxPAPC resulted in significant upregulation of HO-1 lev-
els that unlike baseline levels vary little in between donor cells
(Figure 3B). oxPAPC treatment also led to the upregulation of sev-
eral proinflammatory cytokines such as Interleukin (IL)-6. There
was a negative correlation between basal HO-1 and levels of proin-
flammatory cytokines (Figure 3C). In addition, basal HO-1 levels
were highly correlated with individual responsiveness to oxPAPC
treatment at thresholds above 2-fold and 7.5-fold (R=−0.57)
when responsiveness was defined as the number of genes that were
regulated above a given threshold per individual. This suggests that
basal HO-1 levels are important in the protection against inflam-
mation and in mitigating multiple cellular responses to oxPAPC
(Romanoski et al., 2011).
The greater importance of basal HO-1 levels as compared to
the level of upregulation has important implications, especially
since these observations have been made in human primary cells
that did not undergo any genetic manipulation. First, if basal
HO-1 expression is an important protective factor against vas-
cular inflammation, why are the higher levels following induction
unable to abrogate the inflammatory process? Second, how func-
tional is the induced HO-1 protein? Third, what would be the ideal
timing for potential therapeutic interventions and how should
HO-1 responses be assessed, by changes in the level of mRNA,
protein, functional activity, or levels of its enzymatic byprod-
ucts? While it appears to be clear that HO-1 functional activ-
ity is important for its vascular protection as will be discussed
in Section “HO System, Enzymatic Byproducts and Protection
Against Atherosclerosis,” there is a possibility that various stim-
uli or microenvironments could lead to changes in the specific
enzymatic activity, which is the HO-1 enzymatic activity/HO-1
protein. Thus, Romanoski et al. (2011) showed that while oxPAPC
treatment led to increased HO-1 mRNA, protein, and enzymatic
activity in HAECs, the HO activity increased in a lesser degree
than the HO-1 protein, suggesting a lower HO specific activity after
treatment with oxPAPC as compared with basal levels. This is con-
sistent with another study that showed a disparity between HO-1
protein and HO activity in a rat model of metabolic syndrome
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FIGURE 2 | Basal HO-1 protects against oxidation and
inflammation. HO-1+/− and HO+/+ (WT) mice were subjected to partial
liver warm ischemia for 90 min followed by 6 h of reperfusion. Two
groups of mice were treated with CoPP. (A) Basal HO-1 mRNA levels,
(B) Post-ischemia reperfusion (IR) HO-1 mRNA levels, (C) Basal HO-1
levels correlated negatively with post-IR serum GPT levels (R2 = 0.69,
p<0.0001) (D) HO-1 fold induction had a positive correlation with sGPT
levels instead (R2 =0.75, p=0.0001). Taken from Tsuchihashi et al.
(2006). Copyright 2006. The American Association of Immunologists,
Inc.
FIGURE 3 | Heme oxygenase-1 is a critical gene in the activation of
endothelial cells by oxPAPC. (A) Visualization of the whole network
consisting of 2000 transcripts, organized into 11 modules, shown by
distinct colors. Network was constructed based on genomic expression
data of HACEs from 149 donors, treated with oxPAPC. Examples of
module enrichment in specific pathways are shown. HO-1 is a “hub” of
gene-gene interactions in the blue module, enriched in redox and sulfur
aminoacid processes. (B) HO-1 mRNA expression. Basal levels varied
approximately ninefold at baseline (black curve) but only approximately
twofold after treatment with oxPAPC (red circles). (C) Basal HO-1 mRNA
levels correlated negatively with IL-6 mRNA expression. Taken from
Romanoski et al. (2011).
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where HO-1 protein was likely modified by nitrosylation resulting
in decreased functionality (Kruger et al., 2006). While our cur-
rent understanding of the biology of HO-1 may not be sufficient
to answer all these questions at the present time, the following
sections attempt to provide information that we hope will help to
address them.
ROLE OF HO-1 AND OTHER ANTIOXIDANT GENES IN
ATHEROSCLEROSIS
Atherosclerosis is an inflammatory process of the vascular wall
characterized by the accumulation of lipids and fibrous ele-
ments in large and medium-sized elastic and muscular arteries
(Lusis, 2000). Infiltrating lipids come from circulating low-density
lipoprotein (LDL) particles that are retained in the vascular wall.
The retention of LDL is favored by its oxidative modification
which leads to activation of endothelial cells, monocyte recruit-
ment with internalization into the vasculature, differentiation
into macrophages and generation of foam cells by increased lipid
uptake. Vascular infiltration of lipids and inflammatory cells fur-
ther enhances oxidative stress and a vicious cycle of inflammation
(Araujo et al., 2002). While the pathogenic role of vascular oxida-
tive stress has been challenged by the argument that oxidative
modifications present in the plaques could be consequential rather
than causal to lesion formation (Stocker and Keaney, 2004), it
does appear that the interplay between prooxidant and antioxidant
factors in the vasculature may determine the degree of ROS gen-
eration in a way that can affect lesion formation. Thus, established
risk factors such as diabetes and cigarette smoking or novel risk
factors such as exposure to air pollution enhance ROS generation
in the vasculature and promote atherogenesis (Araujo, 2011). Part
of these actions may be mediated by activation of NADPH oxidase,
which has been shown to be an important source of vascular ROS
and deficiency of its p47phox subunit results in decreased ather-
osclerotic lesion formation in ApoE null mice (Barry-Lane et al.,
2001). On the other hand, organisms have numerous antioxidant
resources that may protect against increased ROS formation in
the vasculature. Some of them are in the circulating blood such
as albumin, bilirubin, or plasma high-density lipoproteins (HDL)
that can exert antioxidant protection. Others are within vascular
cells and include a large number of antioxidant genes and phase-
2 detoxifying enzymes regulated by the transcription factor Nrf2
(NFE2 related factor 2). HO-1 is among those Nrf2-target genes,
which is significantly expressed in all main cell types present in
mouse and human atherosclerotic lesions, such as endothelial cells
(EC), macrophages, and smooth muscle cells (SMCs; Wang et al.,
1998; Ishikawa et al., 2001b).
HEME OXYGENASE-1 AND OTHER ANTIOXIDANT GENES PROTECT
AGAINST ATHEROSCLEROSIS
The importance of HO-1 expression in the protection against
human atherosclerotic lesions has been emphasized by various
genetic population studies, which have shown that a GT length
polymorphism in the promoter region of the human HO-1 gene
is related to susceptibility for atherosclerosis. Thus, a shorter num-
ber of repeats has been associated with decreased susceptibility to
coronary artery disease (CAD) in diabetic Japanese (Kaneda et al.,
2002) and Chinese (Chen et al., 2002) populations, abdominal
aortic aneurysms (Schillinger et al., 2002) and post-angioplasty
restenosis, in both coronary (Chen et al., 2004) and peripheral
arteries (Exner et al., 2001) in comparison with a longer number
of repeats. Short GT variants (S) are likely to result in increased
HO-1 expression in comparison with long variants (L) as judged by
reporter transfection assays (Yamada et al., 2000), even though the
cutoff to differentiate between S and L variants have been different
among various studies. This was confirmed in human umbili-
cal vein endothelial cells (HUVECs). Cells carrying the S allele
exhibited higher levels of HO-1 mRNA, protein, and HO activity
than cells carrying the L allele (Taha et al., 2010). While HO-1
deficiency is very rare in humans, additional confirmation of the
importance of HO-1 against vascular inflammation derives from
the first autopsy report of a HO-1 deficient 6-year-old boy who
exhibited hyperlipidemia (Yachie et al., 1999), foamy macrophages
in the liver as well as fatty streaks and fibrous plaques in the aorta
(Kawashima et al., 2002). In addition, HO-1 deficiency led to very
high concentrations of circulating heme and damage to vascular
endothelium that was probably mediated through the generation
of oxidized forms of LDL (Jeney et al., 2002) which could have con-
tributed to atherosclerotic lesion formation. It is unclear however
whether these changes can be solely attributed to HO-1 deficiency
since this boy had undergone a long-term steroid treatment for
a presumptive diagnosis of juvenile rheumatoid arthritis that was
not confirmed upon pathological examination (Kawashima et al.,
2002).
We and others have shown that HO-1 is an antiatherogenic
gene in animal models (Ishikawa et al., 2001a,b; Juan et al., 2001;
Yet et al., 2003; Orozco et al., 2007) as summarized in Table 1. Sys-
temic lack of HO-1 has been reported to promote atherosclerosis in
ApoE null mice (Yet et al., 2003) as well as aortitis in chow-fed old
C57BL/6 mice (Ishikawa et al., 2012), while its overexpression by
adenoviral means results in decreased atherosclerotic lesions (Juan
et al., 2001). Likewise, pharmacological manipulation of the gene
results in similar effects. Thus, administration of hemin results
in significant HO-1 upregulation and decreased atherogenesis in
LDLR−/− mice (Ishikawa et al., 2001b), ApoE−/− mice (Cheng
et al., 2009), and rabbits fed a high fat diet (Li et al., 2011; Liu et al.,
2012). Since increased expression of HO-1 carries the danger of
increased release of ferrous iron (Fe2+) and exacerbation of iron-
mediated ROS formation, Ishikawa et al. (2001b) administered
iron-chelating deferoxamine to LDLR−/− mice that were treated
with hemin to avoid this potential problem. However, subsequent
studies in ApoE−/− mice and rabbits showed that this was not
necessary (Cheng et al., 2009; Li et al., 2011; Liu et al., 2012). This
is likely due to the fact that HO-1 upregulation colocalizes with
increased expression of ferritin in atherosclerotic lesions, which
may ensure safe disposal of the released Fe2+.
On the other hand, inhibition of HO enzymatic activity by
SnPPIX leads to enhanced atherosclerotic lesions in LDL-R−/−
mice (Ishikawa et al., 2001b), Watanabe hyperlipidemic rabbits
(Ishikawa et al., 2001a) and rabbits fed a high fat diet (Li et al., 2011;
Liu et al., 2012; Table 1). In addition, inhibition of HO enzymatic
activity by ZnPPIX augmented plaque vulnerability in ApoE null
mice by decreasing the relative cap thickness and intimal surface
area of SMC, at the same time of increasing the lipid content and
the degree of core necrosis (Cheng et al., 2009). It is clear then that
modulation of HO-1 expression significantly alters atherogenesis
in various animal models. The different degrees how atherogenesis
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was affected in all these studies may have to do with differences
in the experimental designs and the inherent characteristics of the
animal models employed (Table 1).
As ROS generation and tissue oxidative stress have been impli-
cated in all stages of atherosclerosis, it appears that HO-1 expres-
sion is protective against the development of both early and
advanced atherosclerotic plaques. HO-1 antioxidant and antiin-
flammatory properties may be crucial against the development of
early plaques (Ishikawa et al., 2001b, 2012; Orozco et al., 2007),
while its antiapoptotic activities can be important in lesion pro-
gression and/or plaque vulnerability for rupture (Cheng et al.,
2009; Li et al., 2011). Interestingly, HO-1 expression could inhibit
maturation of dendritic cells (Chauveau et al., 2005) and may
modulate antigen presentation and participate in macrophage dif-
ferentiation/polarization, phenomena that could be particularly
important in the development of early stage lesions. On the other
hand, as intraplaque hemorrhage and accumulation of heme/iron
are an important component in lesion progression, HO-1 expres-
sion could be important to ensure catabolism of the heme groups
and recycling of iron, which could affect the development of
advanced plaques as well.
Heme oxygenase-1 antiatherogenic properties parallel its vas-
cular protective effects in other models of vascular inflammation
such as post-angioplasty restenosis (Duckers et al., 2001; Tulis et al.,
2001), allograft rejection (Araujo et al., 2003), and ischemia reper-
fusion (Tsuchihashi et al., 2006). Like HO-1, other Nrf2-regulated
antioxidant genes such as glutamate-cysteine ligase, modifier sub-
unit (Gclm), glutamate-cysteine ligase, catalytic subunit (Gclc),
peroxiredoxin 2, glutathione peroxidase, have been shown to pro-
tect against atherosclerosis. Thus, while deficiency of Gclm accel-
erates advanced atherosclerosis in ApoE null mice, overexpression
of Gclc results in the opposite (Callegari et al., 2011). Systemic defi-
ciency of peroxiredoxin or in bone marrow-derived cells enhances
atherosclerotic lesions in ApoE null mice (Park et al., 2011). Sim-
ilarly, deficiency of glutathione peroxidase exacerbates diabetes
mellitus-associated atherogenesis in ApoE null mice (Lewis et al.,
2007). On the other hand, adenoviral administration of endothe-
lial cell Superoxide dismutase (EC-SOD; Laukkanen et al., 2002;
Brasen et al., 2007), CuZnSOD (Durand et al., 2005), and catalase
(Durand et al., 2005) inhibit post-angioplasty restenosis instead.
Overall, HO-1 and several antioxidant genes, all regulated by Nrf2,
exert protection against atherosclerosis.
Nrf2 TRANSCRIPTION FACTOR PARADOXICALLY PROMOTE
ATHEROSCLEROSIS
The substantial evidence in support of the antiatherogenic role of
several Nrf2-regulated antioxidant genes led to the hypothesis that
this transcription factor should play an inhibitory role of athero-
genesis as well. Surprisingly, we and others have reported three
separate studies showing that Nrf2 deficiency in gene-targeted
mice leads to decreased atherosclerotic lesions in ApoE null mice
(Sussan et al., 2008; Barajas et al., 2011; Freigang et al., 2011), sug-
gesting that its expression may play a proatherogenic role despite
its antioxidant actions. Nrf2−/−ApoE−/− mice developed reduced
aortic atherosclerosis as compared to Nrf2+/−ApoE−/− (Barajas
et al., 2011; Freigang et al., 2011) or Nrf2+/+ApoE−/− controls
(Sussan et al., 2008; Barajas et al., 2011). The type of diet appears
to be an important modulating factor as these effects were only
seen in males when mice were fed a chow diet (Barajas et al.,
2011).
Various putative mechanisms, as shown in Figure 4, could
mediate Nrf2 proatherogenic effects as recently discussed in an
editorial article (Araujo, 2012): (1) Nrf2 expression leads to
increased levels of plasma non-HDL cholesterol in Chow-fed
ApoE null mice, likely via enhancing liver lipogenesis (Huang
et al., 2010; Barajas et al., 2011), (2) Nrf2 promotes foam cell
formation, partially due to upregulation of the CD36 scavenger
receptor (Ishii et al., 2004; Barajas et al., 2011), (3) Nrf2 enhances
increased expression of IL-1α in macrophages which may promote
greater monocyte migration to the lesions (Burns and Furie, 1998;
Freigang et al., 2011), and (4) Nrf2 may regulate the differentiation
of macrophages to subtypes different to the classical M1 and M2,
named Mox (Kadl et al., 2010) and possibly Mhem (Boyle et al.,
2011, 2012), with functions in atherosclerotic lesion formation still
to be determined.
The opposite effects of HO-1 and Nrf2 in atherogenesis shown
in Figure 4, underline the high degree of complexity of path-
ways involved in the response to prooxidative and proatherogenic
stimuli. In addition, it appears that the level of regulation or inter-
vention upon these responses is quite important as downstream
interventions such as deletion of antioxidant genes like HO-1
result in exacerbation of atherosclerosis but a more upstream
level of intervention, such as deletion of Nrf2 transcription factor,
results in the opposite. It is therefore quite important to under-
stand how HO-1, as well as other antioxidant genes, exert their
antiatherogenic effects.
HEME OXYGENASE-1 ANTIATHEROGENIC EFFECTS:
SYSTEMIC VS. VASCULAR MECHANISMS
Heme oxygenase-1 is ubiquitously expressed and highly upregu-
lated in all the main cell types present in human (Wang et al.,
1998) and murine atherosclerotic lesions (Ishikawa et al., 2001b),
including endothelial cells, macrophages, and SMCs, but it is very
low in neighboring unaffected vascular tissue. Such upregulation is
particularly noticeable in macrophages, foam cells, and endothe-
lial cells (Ishikawa et al., 2001b). The overall protective effects
of HO-1 have been well documented and the subject of recent
reviews (Morita, 2005; Abraham and Kappas, 2008; Soares and
Bach, 2009; Durante, 2011) but the importance of the tissue and
cellular localization as well as precise mechanisms responsible for
these effects remain unclear. Several studies have addressed the role
of HO-1 in atherogenesis as mentioned in the previous section
(Table 1). For the most part, these studies have used systemic
modulation of either HO-1 expression and/or HO activity, which
occurs in both vascular and non-vascular cells, with subsequent
alteration of oxidant and inflammatory parameters in the circu-
lating blood. It is possible that HO-1 antiatherogenic actions are
due to a combination of systemic and local vascular mechanisms.
SYSTEMIC EFFECTS
Systemic modulation of HO-1 expression levels or activity can lead
to changes in the systemic levels of its enzymatic byproducts that
could mediate some of the effects in the vasculature. Thus, sys-
temic transgenic mice that overexpressed HO-1 by only∼30–50%
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FIGURE 4 | Differential effects of HO-1 and NRF2 in atherosclerosis.
Prooxidant and proatherogenic stimuli such as oxLDL and oxPAPC can induce
HO-1 expression in vascular cells via Nrf2 activation or other pathways. HO-1
expression leads to decreased ROS generation, decreased inflammatory
events such as lower expression of cell adhesion molecules (CAMs) and
decreased secretion of inflammatory factors such as monocyte chemotactic
protein (MCP)-1 and IL-8. HO-1 also leads to decreased foam cell formation
and changes in LDL and HDL lipoproteins, all of which lead to decreased
atherogenesis. Nrf2 is bound by chaperone Keap1 in the cytosol. Electrophilic
agents lead to dissociation of the Nrf2-Keap1 complex, with release of Nrf2
and nuclear translocation that leads to the induction of HO-1 and several other
antioxidant genes that result in decreased ROS formation. However, Nrf2
expression promotes atherosclerotic lesion development. Possible
mechanisms include: (1) increased macrophage lipid uptake and foam cell
formation, (2) increased lipogenesis and greater levels of non-HDL plasma
cholesterol, (3) greater macrophage secretion of IL-1 and monocyte migration
to the vessels, and (4) possible macrophage differentiation into a
proatherosclerotic phenotype.
in the liver over WT controls, exhibited a modest increase in blood
unconjugated bilirubin (Araujo et al., 2003). Likewise, I.P. treat-
ment of rabbits with hemin for 12 weeks led to increased HbCo
levels while I.P. treatment with inhibitor SnPPIX for similar time
led to the opposite (Li et al., 2011). In humans, small variations in
bilirubin levels translate into clinical effects.
Changes in blood or vascular concentrations of HO byproducts
could lead to alterations in plasma lipoproteins that may affect
susceptibility to atherogenesis. Indeed, HO-1 null mice exhibit
increased levels of plasma lipid peroxides (Ishikawa et al., 2012)
that are parallel to their increased levels of lipid peroxides and pro-
tein carbonyls in the liver and kidneys (Poss and Tonegawa, 1997).
Likewise, inhibition of HO activity by ZnPPIX leads to increased
serum levels of oxLDL (Liu et al., 2012). It is possible that HO-1
deficiency or inhibition of HO enzymatic activity could lead to
increased levels of circulating heme which may mediate lipid per-
oxidation in plasma lipoproteins, resulting in oxidized LDL (Balla
et al., 1991) and lipid oxidation in atherosclerotic plaques (Nagy
et al., 2010). Indeed, the 6-year-old boy, deficient in HO-1, was
reported to have chronic intravascular hemolysis (Yachie et al.,
1999) resulting in very high concentrations of circulating heme
and a high proportion of methemoglobin (Jeney et al., 2002). The
latter is a form of the oxygen-carrying hemoglobin that can not
bind oxygen and releases iron in a greater degree than the nor-
mal oxy-hemoglobin with the subsequent potential of promoting
oxidative injury and endothelial cell toxicity (Jeney et al., 2002).
Therefore, HO-1 mediated disposal of heme groups may help to
decrease systemic lipid peroxidation, generation of oxidized LDL
and cellular injury (Figure 4).
Heme oxygenase-1 systemic effects also appear to involve HDL
lipoproteins as HO-1 null mice exhibit decreased levels of paraox-
onase activity and altered ratio of apoAI to apoAII proteins, which
are likely to alter HDL function (Ishikawa et al., 2012). Therefore,
HO-1 expression may protect against LDL oxidation or decrease
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its susceptibility to oxidation as it alters HDL protective qualities
(Figure 4). In addition, HO-1 expression may also affect inflam-
matory mediators at a systemic level, as HO-1 null mice have been
reported to exhibit greater plasma levels of monocyte chemotactic
protein (MCP)-1 protein and increased levels of MCP-1 mRNA in
circulating leukocytes as compared with wild-type mice (Pittock
et al., 2005).
Heme oxygenase-1 and BVR, the latter responsible for the con-
version of biliverdin into bilirubin, have been reported to exert
beneficial effects in metabolic pathways. For instance, BVR has
been shown to be a member of the insulin receptor substrate fam-
ily (Lerner-Marmarosh et al., 2005) with pleiotropic functions that
include effects on metabolism and cytoprotection (Kapitulnik and
Maines, 2009). In addition, HO-1 has been shown to be induced
by apoAI mimetic peptides and mediate some of their beneficial
effects on decreasing endothelial cell sloughing and improving
vascular reactivity in a rat model of diabetes (Kruger et al., 2005).
Whether these effects are due to a systemic or a vascular level
of action is not clear. HO-1 null mice do not exhibit alteration
of plasma glucose and/or lipid levels indicative of overt diabetes,
glucose intolerance, or other frank metabolic disorders. It might
be possible that HO-1 deficient mice may experience upregula-
tion of other compensatory mechanisms that could inhibit the
development of obvious metabolic abnormalities.
In addition to these systemic effects, it also appears that vascular
local expression is important. Indeed, adenoviral HO-1 overex-
pression via intracardiac administration, resulting in both aortic
and liver overexpression, confers protection against atherosclero-
sis whereas tail vein administration, only resulting in hepatic but
not aortic overexpression, does not (Juan et al., 2001). Although
the contribution of systemic effects can not be ruled out by this
approach since adenoviral administration via tail vein may have
elicited a degree of systemic inflammation that could have masked
the effects of sole hepatic HO-1 overexpression, the study does
underline the importance of HO-1 expression in the vasculature.
ENDOTHELIAL CELLS
The vessels contain a monolayer of endothelial cells which rep-
resent the first cellular component that any infiltrating lipid or
inflammatory cell encounter as they enter the vascular wall. The
activation of endothelial cells leading to the expression of cell adhe-
sion molecules (CAMs) and proinflammatory factors may be key
in atherogenesis. Therefore, HO-1 expression in endothelial cells
can be an important factor in the prevention against atherosclero-
sis. Indeed, Romanoski et al. (2011) recently reported that HO-1
expression in endothelial cells constitutes a critical gene in the
global response of endothelial cells against oxidized phospholipids.
In this study, a “systems-level” approach was used to understand
the multiplicity of pathways that are elicited in HAECs, from 149
donors, in response to a treatment with oxPAPC, products of
the oxidation of phospholipid PAPC (1-palmitoyl-2-arachidonyl-
sn-glycero-3-phosphorylcholine), which are generated during the
oxidation of LDL particles and known to induce HO-1. The
approach took advantage of naturally occurring genetic variations
in the human population that perturbed individual gene expres-
sion patterns with and without oxPAPC treatment, which enabled
the construction of a gene co-expression network, consisting of
11 modules (groups) of tightly connected genes. Some genes
exhibited many more connections than others (“hubs”), which
in general, appear to be much more important in the functioning
of the cell/organism as a whole. Notably, HO-1 emerged as a “hub”
in one of the most interesting modules (blue module, Figure 3A),
with various degrees of connection with other antioxidant genes
(e.g. NQO1, Gclm), unfolded protein response (UPR) as well as
transcription factors (e.g. Nrf2, MAFF).
This approach not only helped to identify novel factors that
could be involved in the regulation of human HO-1 such as
G-protein coupled receptor (GPR)-39 but also unraveled clues
about the dynamics of the HO-1 response to oxPAPC in human
subjects. While HAECs from the 149 donors exhibited a nine-
fold difference between extremes of HO-1 expression, they only
exhibited a twofold difference after treatment with oxPAPC,
suggesting that there was a ceiling to oxPAPC-induced HO-
1 expression in this system. Importantly, basal HO-1 expres-
sion levels, rather than HO-1 levels after oxPAPC treatment,
strongly correlated negatively with the expression of proinflam-
matory cytokines such as IL-6 (r =−0.36, p= 1.37 e − 06), IL-8
(r =−0.28, p= 2.41 e − 04), CAMs such as VCAM1 (r =−0.22,
p= 3.31 e − 03), UPR such as Activating factor (ATF)3 (r =−0.40,
p= 5.01e − 08). Silencing of HO-1 by siRNA resulted in upreg-
ulation of many of the same genes (Romanoski et al., 2011).
Altogether, this suggests that basal HO-1 levels are major deter-
minants in the protection against inflammation and possibly
atherogenesis, in parallel with our similar findings in the mod-
els of liver ischemia reperfusion (Tsuchihashi et al., 2006) and
cardiac allograft rejection (see Heme Oxygenase-1 and Vascu-
lar Inflammation: Importance of Basal Levels). In addition, it
will be important to determine whether GPR39 or other genetic
factors could help explain the ninefold difference observed in
basal HO-1 in HAECs, especially since the (GT)n polymor-
phisms data could not explain that variation (Romanoski et al.,
2011).
Heme oxygenase-1 expression in endothelial cells leads
to decreased expression of vascular cell adhesion molecule-1
(VCAM-1) as well as the expression and release of chemokines
and proinflammatory cytokines such as CC-chemokine ligand
(CCL)2, also known as MCP-1 (Sacerdoti et al., 2005). Taha et
al. also reported that HUVECs collected from individuals exhib-
ited differences in their basal (unstimulated) HO-1 levels that were
dependent on their genotype for the (GT)n microsatellite DNA.
In this study, alleles were classified as Short (S), Medium (M),
and Long (L) based on the number of GT repeats, ≤23, 24–28,
and ≥29 repeats, respectively. Cells carrying the S allele exhibited
higher HO-1 basal levels than those carrying the M and/or L alle-
les. Likewise, similar differences in expression levels ensued after
treatment with H2O2, CoPP, LPS, 15d-PGJ2b, but not after treat-
ment with hemin or in the presence of hypoxia where there were
no differences. Here also, cells with the S allele, with higher basal
HO-1 levels exhibited lower basal levels of IL1β, IL-6, and ICAM-
1 (Taha et al., 2010). Despite the potential differences in behavior
between endothelial cells in culture and those in the vascular wall
in vivo, these studies support a protective role for HO-1 expression
in endothelial cells that could represent a significant portion of its
protection against atherogenesis.
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Heme oxygenase-1 expression in endothelial cells could also
play a role in the protection against atherosclerosis induced by
environmental factors such as smoking and exposure to air pollu-
tion, which has been shown to lead to increased atherosclerosis in
several animal models (Araujo, 2011). Indeed, it is upregulated in
systemic tissues in response to the exposure to ambient ultrafine
particles and its upregulation in a cell line of human microvascular
endothelial cells, in response to oxPAPC and diesel exhaust parti-
cle (DEP) chemicals, occurs in a synergistic manner (Gong et al.,
2007). It remains to be determined whether HO-1 plays indeed a
protective role in this context.
MACROPHAGES, DENDRITIC CELLS, AND LYMPHOCYTES
Macrophages are the main inflammatory cells that infiltrate the
vascular wall in atherogenesis, involved in the initiation as well as
progression of atherosclerotic lesions. Upon activation of endothe-
lial cells, blood monocytes are recruited to the site of injury and/or
EC activation where cytokines and/or chemokines are released,
adhere to the endothelium and transmigrate to the subendothelial
space where they further differentiate into macrophages. HO-1 is
highly upregulated in macrophages in atherosclerotic lesions and
several lines of evidence support its protective antiatherogenic
role in these cells. First, HO-1 has been shown to exert antiox-
idant and antiinflammatory effects in macrophages (Lee et al.,
2003; Philippidis et al., 2004; Levonen et al., 2007; Orozco et al.,
2007). Indeed, we have reported that decreased or absent HO-1
expression in peritoneal macrophages results in enhanced ROS
formation and increased inflammatory cytokines such as MCP-1,
interleukin 6 (IL-6), and the murine interleukin 8 homolog (KC;
Orozco et al., 2007; Figure 5A). Second, HO-1 expression influ-
ences lipid loading and foam cell formation as both partial and
total HO-1 deficiency results in enhanced lipid loading and foam
cell formation in peritoneal macrophages treated with oxLDL,
at least partially mediated by increased expression of the scav-
enger receptor A (SR-A; Orozco et al., 2007). Third, lack of HO-1
expression in bone marrow-derived cells resulted in atheroscle-
rotic plaques with a larger inflammatory component, suggestive
of greater vulnerability for rupture (Orozco et al., 2007). Irra-
diated LDL-R−/− mice with their bone marrow reconstituted
with HO-1−/− donor cells resulted in plaques with increased
macrophage area as compared with control mice reconstituted
with WT bone marrow (Orozco et al., 2007). Fourth, HO-1
expression may play a role in macrophage differentiation and
polarization (Figure 5B).
Heme oxygenase-1 antiatherogenic actions may also be due to
its expression in other myelocytic or lymphocytic cells. Thus, it has
been shown that HO-1 is expressed in immature dendritic cells and
its overexpression inhibits dentritic cell maturation (Chauveau
et al., 2005) which may play a role in atherogenesis. Several studies
have highlighted a prominent role of dendritic cells in atheroscle-
rotic lesions (Llodra et al., 2004; Yilmaz et al., 2004; Bobryshev,
2005) as they are present especially in regions of atherosclerotic
plaques that are prone to rupture (Yilmaz et al., 2004) and its
emigration from the lesions to lymph nodes associate with reduc-
tion in the size of atherosclerotic plaques (Llodra et al., 2004).
Antigen presentation by dendritic cells as well as lymphocyte infil-
tration and the triggering of Th1 immune responses appear to
play a role in atherosclerosis (Bobryshev, 2010; Manthey and Zer-
necke, 2011). Atherosclerotic lesion development is favored by Th1
responses while it is inhibited by conditions that promote a Th2
response (Minamino et al., 2001). HO-1 overexpression may lead
to a switch from a Th1 to a Th2 response (Ke et al., 2000, 2001).
These immunomodulatory actions parallel the effects of HO-1
expression against acute rejection response in models of allo-
graft transplantation (Araujo et al., 2003). As macrophages can
also function as antigen-presenting cells, they can play a role in
the modulation of Th immune responses. Therefore, macrophage
HO-1 expression could not only affect their function as effectors
but also as presenting cells.
Macrophage differentiation, polarization, and function could
indeed be affected by HO-1 expression. Upon differentiation,
macrophages may polarize into distinct subsets with character-
istic phenotypes and likely to exhibit different behaviors in ath-
erosclerotic lesion formation, as schematized in Figure 5B. The
first subtypes of polarized macrophages that were described were
named as M1 and M2. Macrophages stimulated by lipopolysac-
charide (LPS) or interferon gamma (IFN-γ) polarize into M1
macrophages, characterized by increased expression of proin-
flammatory molecules such as IL-1β, IL-6, IL-8, tumor necrosis
factor alpha (TNF-α) as well as inducible nitric oxide synthase
(iNOS), which typically trigger Th1 T cell responses (Wuttge
et al., 2001; Yan and Hansson, 2007; Krausgruber et al., 2011).
On the other hand, M2 macrophages stimulated by IL-4 (M2a),
immune complexes (M2b),or IL-10/IL-13 (M2c) are characterized
by increased expression of antiinflammatory molecules includ-
ing IL-10, arginase-1 (Arg1), mannose receptor, tumor growth
factor beta (TGF-β), which are likely to play an antiatheroscle-
rotic role (Wilson, 2010). While both types of macrophages have
been identified in atherosclerotic lesions (Bouhlel et al., 2007)
and exhibit low expression of HO-1, it has been reported that
increased HO-1 expression may contribute to a M2 macrophage
activation profile, which is involved in the resolution of inflam-
mation (Weis et al., 2009). Furthermore, different macrophage
subtypes have been recently described where expression of HO-1
may play a characteristic role, either as a part of their pheno-
typic traits or in the modulation of their potential role in lesion
formation.
Treatment of macrophages with oxPAPC led to a phenotypic
switch of both M1 and M2 phenotypes into a new subtype
named as Mox, characterized by exclusive upregulation of redox-
regulated genes such as HO-1, sulforedoxin-1 (Srxn1), glutamate-
cysteine ligase, modifier subunit (Gclm), glutamate-cysteine ligase,
catalytic subunit (Gclc), thioredoxin reductase (Txnrd) 1, but
also vascular endothelial growth factor (VEGF), nuclear recep-
tor Nr4A2 (Nurr1) and Trb3 (Kadl et al., 2010). Approximately
30% of macrophages present in atherosclerotic lesions developed
by LDLR−/− mice had this phenotype. Interestingly, polarization
into a Mox phenotype was Nrf2 dependent and also charac-
terized by a decreased phagocytic activity (Kadl et al., 2010),
which raises the question whether this macrophage could exert
proatherosclerotic actions, despite its high expression of HO-
1 and other antioxidant genes (Araujo, 2012). More recently,
another subtype of macrophages has been described in associa-
tion with intraplaque hemorrhage named as Mhem, characterized
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FIGURE 5 | Heme oxygenase-1 inhibits macrophage
proinflammatory activity. (A) Peritoneal macrophages from HO-1+/+,
HO-1+/−, and HO-1+/+ mice were cultured in the presence or absence of
oxLDL 50µg/ml for 6 h. IL-6 and MCP-1 were determined by ELISA.
*p<0.001 as compared with controls. Data taken from Orozco et al.
(2007). (B) HO-1 expression varies in different subtypes of macrophages.
Upon monocyte differentiation into macrophages, they can polarize into
one of the five proposed subtypes, M1, M2, M4, Mox, and Mhem. Each
subtype is induced by specific stimuli as shown along the arrows that
derive from the macrophage Mø atop, and characterized by a set of
phenotypic markers and/or gene expression shown below each one of
them. While some of macrophage subtypes are proposed to simulate
atherogenesis such as M1 and M4, others are proposed to inhibit lesion
development such as M2 and Mhem. Mox macrophages, generated
after treatment with oxPAPC, are dependent on Nrf2 with a role in
atherogenesis still to be determined.
by increased expression of IL-10 and CD163, macrophage scav-
enge receptor for hemoglobin-haptoglobin complex (Hb-Hp),
low expression of human leukocyte antigen-DR (HLA-DR; Boyle
et al., 2009). Mhem macrophages also exhibit increased expres-
sion of HO-1, dependent on Nrf2 (Boyle et al., 2011) in addition
to activating transcription factor 1 (Boyle et al., 2012). These
macrophages could play an antiatherogenic role by virtue of
its participation in Hb-Hp clearance, with subsequent reduc-
tion in ROS formation and antiinflammatory effects. One last
macrophage subtype named M4 is induced by CXCL4 and char-
acterized by a gene expression profile that contained both M1
and M2 genes (Gleissner et al., 2010). Unlike Mhem macrophages
which have increased expression of CD163 (also known as ED2)
and HO-1, M4 macrophages do not express Hb-Hp scavenger
receptor CD163 and do not upregulate HO-1 expression (Gleiss-
ner, 2012). M4 macrophages appear to play a proatherogenic role,
which is consistent with the ∼60% decrease in aortic atheroscle-
rotic lesions exhibited by CXCL-4−/−ApoE−/−mice (Sachais et al.,
2007). It is clear then that macrophage differentiation and polar-
ization is quite complex as they may respond to the very specific
microenvironments that monocytes and macrophages encounter.
These various macrophage subtypes exhibit different patterns of
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HO-1 expression (Figure 5B) and it is unknown whether HO-1
could play a role in the polarization into any of these subtypes or
in the function that these macrophages could have in atherogen-
esis. For instance, Nrf2 expression appears to be essential in the
generation of Mox macrophages and participate in the generation
of Mhem macrophages as well, both of which express high lev-
els of HO-1 but perhaps with different roles in the development
of atherosclerotic lesions. Thus, the role for HO-1 expression in
these various macrophage subtypes still need to be determined
(Figure 5B).
SMOOTH MUSCLE CELLS
Heme oxygenase-1 is also expressed in vascular SMCs and could
play an important role in the protection against atherogenesis. This
is supported by evidence accrued in the model of post-angioplasty
restenosis where the proliferative response of SMCs constitutes a
fundamental aspect of the disease (Duckers et al., 2001; Tulis et al.,
2001). SMC proliferative response has been shown to be important
in the progression of atherosclerotic plaques as well. On the other
hand, SMC and their synthesis of collagen are important contrib-
utors to plaque composition and stability as thicker fibrous caps
are associated with lesser vulnerability for rupture. As mentioned
above, inhibition of HO activity by ZnPPIX decreased relative cap
thickness and intimal surface of SMC in ApoE null mice (Cheng
et al., 2009). Likewise, administration of SnPPIX to rabbits resulted
in plaques with decreased content of SMC while hemin led to the
opposite (Li et al., 2011). Whether these effects are due to HO-1
expression in SMC per se or due its expression in neighboring cells
is not clear.
In summary, the overall antiatherogenic role of HO-1 expres-
sion may be due to a combination of complex systemic and
vascular local effects that converge in the inhibition of lipid per-
oxidation with effects on circulating lipoproteins, decrease in the
activation of endothelial cells, inhibition of macrophage proin-
flammatory activity and possible participation in its differentia-
tion/polarization, inhibition of dendritic cell maturation as well
as modulation of immune-mediated responses and regulation of
the proliferative response of SMCs.
HEME OXYGENASE SYSTEM, ENZYMATIC BYPRODUCTS,
AND PROTECTION AGAINST ATHEROSCLEROSIS
Heme oxygenase-1 is not only expressed ubiquitously in the body
but it is also located in several compartments within the cell. It
is a 32-kDa protein most abundantly located in the microsomal
fraction, with a short transmembrane segment of ∼ 2 kDa in the
endoplasmic reticulum membrane and ∼30 kDa cytosolic por-
tion. However, HO-1 can also be found in the plasma membrane,
associated with caveolae (Kim et al., 2004), in the mitochondria
(Converso et al., 2006) and in the nucleus (Lin et al., 2007, 2008).
Interestingly, while nuclear HO-1 was shown to be catalytically
inactive (Lin et al., 2008), it appeared to modulate the expression
of itself (Lin et al., 2008) and that of activating protein (AP)-1
(Lin et al., 2007). Although HO-1 does not have DNA binding
domains in its sequence and no definite protein-protein inter-
actions have been demonstrated, additional work is required to
elucidate whether HO-1 may play a role in transcriptional regula-
tion. It appears that the biological effects due to HO-1 expression
are mostly due to its enzymatic activity, since its pharmacolog-
ical inhibition results in almost complete abolishment of those
biological effects. Therefore, the various byproducts of HO enzy-
matic activity could be considered as its “branches” or “arms of
action.”
BILIVERDIN/BILIRUBIN
There is evidence that biliverdin/bilirubin can mediate some
of HO-1 antiatherogenic effects. Exogenous administration of
biliverdin, which is promptly converted to bilirubin, appears to
be effective in inhibiting atherogenesis in ApoE null mice (per-
sonal communication from Miguel Soares, Gulbenkian Institute
of Sciences, Portugal). This parallels the protective effects of
biliverdin and/or bilirubin in other models of vascular inflam-
mation, such as liver ischemia reperfusion injury (Fondevila et al.,
2004), cardiac allograft graft rejection (Yamashita et al., 2004),
and post-angioplasty restenosis (Ollinger et al., 2005, 2007). In
addition, epidemiological studies show an inverse relationship
of plasma or serum bilirubin concentrations and the risk of
CAD (Schwertner et al., 1994; Schwertner and Vitek, 2008), at
a strength that was found to be similar to that of smoking, ele-
vated systolic blood pressure, and low HDL cholesterol (Schwert-
ner et al., 1994; Hopkins et al., 1996; Schwertner, 1998). Serum
bilirubin concentrations are inversely correlated with the sever-
ity of atherosclerosis in men (Novotny and Vitek, 2003). Thus,
individuals with Gilbert syndrome, characterized by increased
levels of circulating unconjugated bilirubin due to a low reac-
tivity of the bilirubin-uridine diphosphate glucuronyl transferase
(bilirubin-UGT) enzyme, exhibit a marked reduction in CHD risk
(Schwertner and Vitek, 2008).
Biliverdin/Biliribin could inhibit atherogenesis through to its
antioxidant properties. Biliverdin’s antioxidant properties appear
to depend on the expression of BVR (Singleton and Laster, 1965)
and its conversion to bilirubin. Indeed, bilirubin is a powerful
antioxidant (Stocker et al., 1987; Stocker and Keaney, 2004) that
could inhibit the oxidation of LDL and other lipids (Neuzil and
Stocker, 1994; Wu et al., 1996), scavenge oxygen radicals (Stocker
et al., 1987) and counteract oxidative stress overall (Schwertner,
1998). The production of bilirubin could participate in an ampli-
fication cycle by getting oxidized into biliverdin and then reduced
back into bilirubin by BVR (Baranano et al., 2002).
Bilirubin also exerts antiinflammatory and antiproliferative
actions that can account for its antiatherogenic effects. Indeed,
congenitally hperbilirubinemic Gunn rats exhibit almost no
neointimal proliferation after balloon injury in comparison with
significant proliferation observed in WT rat controls (Ollinger
et al., 2005). Likewise, 1-h local treatment of a rat carotid artery
with biliverdin significantly reduces neointima formation after
balloon injury (Ollinger et al., 2007). These effects were medi-
ated by inhibition of cell cycle progression and proliferation of
SMC (Ollinger et al., 2005, 2007), which could protect against ath-
erosclerosis (Sriram and Patterson, 2001). Various mechanisms
may explain antiproliferative effects of Biliverdin/Bilirubin such
as: (1) Overexpression of cdk inhibitor p53 resulting in increased
apoptosis of rat SMCs (Liu et al., 2002), (2) Inhibition of cyclin A,
D1 and E, YY1 and cdk 2 expression, leading to hypophosphory-
lation of the retinoblastoma tumor suppressor protein (Rb) and
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cell cycle arrest (Ollinger et al., 2005), (3) Inhibition of JNK acti-
vation (Ollinger et al., 2007), and (4) Modulation of p38 MAPK
activation (Ollinger et al., 2005). Interestingly, bilirubin/biliverdin
have been shown to be ligands of the aryl hydrocarbon receptor
(Ahr) in mouse hepatoma hepa 1c1c7 cells (Sinal and Bend, 1997;
Phelan et al., 1998) and SMCs from Ahr KO mouse aortas exhibit
a prolonged cell cycle time as compared with controls (Ollinger
et al., 2007), which suggest that Ahr activation could participate in
the regulation of proliferation of SMCs. In support of this possi-
bility, Ahr null mice exhibit decreased atherosclerosis in the ApoE
null background (Wu et al., 2011).
All this evidence, together with the findings that relate
the participation of BVR in insulin-induced pathways (Lerner-
Marmarosh et al., 2005; Kapitulnik and Maines, 2009), make
this arm attractive candidate for pharmacological intervention.
Thus, development of compounds that either increase the endoge-
nous levels of biliverdin/bilirubin by targeting genes involved in
the metabolism or resemble their biological activity can lead to
promising new therapies.
CARBON MONOXIDE
The generation of CO constitutes the second arm how HO-1 may
prevent atherosclerosis. In fact, administration of CO by inhala-
tion results in suppression of intimal hyperplasia associated with
chronic graft rejection and balloon injury (Otterbein et al., 2003).
Although there are no reports yet about CO inhibitory effects
on atherosclerotic lesions due to hyperlipidemia, there are sev-
eral lines of evidence and potential mechanisms that make it
very likely. First, CO exhibits cytoprotective properties in vascular
endothelial cells by inhibiting apoptosis, likely through activa-
tion of p38 mitogen-activated protein kinase (MAPK) signaling
pathway (Brouard et al., 2000). Second, CO exerts antiinflam-
matory effects. Indeed, CO has been shown to modulate the
response of monocytes/macrophages to bacterial LPS (Otterbein
et al., 2000), decrease macrophage toll-like receptor (TLR) sig-
naling with downstream activation of NF-kB (Wang et al., 2009)
and inhibit expression of GM-CSF with probable alteration of
macrophage differentiation (Sarady et al., 2002). Inhalation of CO
leads to decreased leukocyte infiltration of rat aortic allografts
(Otterbein et al., 2003), accompanied by decreased expression
of proinflammatory genes associated with macrophage activation
(Otterbein et al., 2000). Interestingly, antiinflammatory effects are
also mediated by activation of the MAPK signaling pathway, but
they appear to require the generation of ROS as inhibition of
ROS in macrophages leads to loss of CO antiinflammatory effects
(Bilban et al., 2008). Third, HO-1 and CO may crosstalk with
Nitric Oxide Synthases (NOS) and NO. Administration of hemin
to rabbits resulted in greater CO levels in the aorta, accompa-
nied by decreased levels of aortic NO and inducible Nitric oxide
synthase (iNOS; Li et al., 2011), while HO inhibition by SnPPIX
or ZnPPIX resulted in the opposite (Li et al., 2011; Liu et al.,
2012). CO might bind and activate guanylate cyclase, leading to
increased intracellular levels of cyclic guanine monophosphate
(cGMP; Morita et al., 1995; Hartsfield, 2002). However, the end
result in this crosstalk between CO and NO may depend on their
relative concentrations as both gaseous molecules compete for
the same enzyme but with different affinities. In addition, the
biological effects due to this interplay between CO and NO may
be characteristic of each cell type. Fourth, CO displays antiprolif-
erative actions in SMCs (Morita et al., 1997), which could account
for a good portion of its beneficial effects in the model of bal-
loon injury (Otterbein et al., 2003). These CO effects require
activation of p38 MAPK pathway, which appears to occur via a
cGMP-dependent mechanism and require activation of guanylate
cyclase as well (Otterbein et al., 2003). Last, there is a possibil-
ity that CO could exert antioxidant effects via binding of the
Fe2+ in heme groups and preventing the oxidation of hemopro-
teins, subsequently inhibiting the release of free heme (Balla et al.,
1993). This mechanism appears to be important in the suppres-
sion of experimental cerebral malaria by CO (Pamplona et al.,
2007).
HEME CATABOLISM AND RELEASE OF IRON
A third arm of action of the HO-1 system with antioxidant effects
consists in the catabolic processing of heme groups, including the
release and safe disposal of ferrous iron (Fe2+). Heme groups,
derived from hemoglobin and other hemoproteins, can exacer-
bate the generation of ROS and membrane lipid peroxidation via
the participation of Fe2+ in the Fenton reaction (Ryter and Tyrrell,
2000). Heme groups consist of a central iron atom in a coordinated
binding to a protoporphyrin, composed of four pyrrole rings. The
oxidative cleavage of this tetrapyrrolic ring leads to the release
of its central Fe2+ with the potential of facilitating its partici-
pation in redox chemistry. This is how in certain circumstances,
overexpression of HO, either HO-1 or HO-2 have been shown
to exert prooxidant effects instead (Lamb et al., 1999; Ryter and
Tyrrell, 2000). However, the simultaneous expression of ferritin,
an important multimeric protein complex with a high capacity for
iron storage, helps to channel the safe disposal for Fe2+. In addi-
tion, it appears that several of the same stimuli that trigger HO-1
upregulation also increase ferritin expression, at the same time
that labile Fe per se can upregulate the expression of heavy-chain
(H-) ferritin, which in association with light-chain (L-) ferritin
subunits lead to the assembly of ferritin protein (Harrison and
Arosio, 1996). Indeed, ferritin expression colocalizes with HO-1
expression in atherosclerotic lesions and in common with HO-
1, ferritin is markedly increased in various cell types present in
atherosclerotic plaques such as myofibroblasts, macrophages, and
endothelial cells, where it may play a protective role against oxi-
dized lipoproteins (Juckett et al., 1995). Coordinate expression
of HO-1 and ferritin can lead to antioxidant effects by different
mechanisms. First, it decreases the bioavailability of Fe2+ to par-
ticipate in redox chemistry. Second, the ferroxidase activity of the
H-chain subunit, leads to the conversion of Fe2+ to Fe3+ and
therefore, decrease in iron prooxidant potential (Balla et al., 1992;
Berberat et al., 2003). Third, multimeric ferritin can bind free
heme with subsequent reduction in its bioavailability (Kadir and
Moore, 1990). The prooxidative effects of HO-1 overexpression
could be seen when increases in HO-1 levels overwhelm concur-
rent expression of ferritin. It seems, however, that these potentially
deleterious effects that are noted in experimental studies are less
likely to occur in normal physiological conditions. Instead, co-
expression of both HO and ferritin appears to play a significant
antioxidant role.
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Overall, it appears that all HO byproducts could contribute
to the HO-1 antiatherogenic effects. It remains to be elucidated
whether these actions are complementary or merely overlapping
and what is the degree of contribution of each one of these arms
of action in the HO-1 global effects.
SUMMARY AND PERSPECTIVES
The overall importance of HO is underlined by its large degree of
evolutionary conservation in all kingdoms of life as it is expressed
in prokaryotic and eukaryotic cells, bacteria, yeasts, protozoa,
plants, invertebrate and vertebrate animals. In all these various
living organisms, HO contributes to the catabolic processing of
hemoproteins and avoidance of the potential toxicity that could
be associated to the release of Fe atoms present on them.
Heme oxygenase appears to exert most of its actions thanks
to its enzymatic activity and the generation of various enzymatic
byproducts that act on a multiplicity of pathways. Therefore, HO
activity can be visualized as a HO system with three branches or
arms of action that consist in: (1) generation of Biliverdin and sub-
sequent reduction to bilirubin, (2) release of CO, and (3) release
and safe disposal of Fe2+. These arms of action modulate var-
ious pathways with a high degree of overlap and/or cross-over,
which may help to ensure the induction of the desired biolog-
ical effects. HO-1 is most abundant in the cytosol, attached to
the smooth endoplasmic reticulum (SER) membrane. However,
its presence in other subcellular localizations such as the plasma
membrane, mitochondria, or nucleus raises the question whether
HO could exert some protein-protein or protein-DNA interac-
tions that could play other roles, such as transcriptional regulation,
which requires further exploration. HO-1 and the HO system in
general are thought to play a critical role in cellular homeostasis
where the presence of complementarity or overlap between the
arms of action could result in some degree of redundancy that can
help to ensure the induction of HO mediated critical effects. These
principles are also seen in the protection against vascular inflam-
mation and atherosclerosis. Thus, HO three arms of action have
various degrees of antioxidant, antiinflammatory, antiapoptotic,
antiproliferative, and immunomodulatory effects, most of which
may play a significant role in the protection against atherosclerotic
lesion formation.
Heme oxygenase-1 has been shown to be a critical gene in
the cellular response against prooxidative stimuli such as oxidized
phospholipids. When considering the cellular response as a whole,
HO-1 acts as a hub of gene-gene interactions that modulate the
triggering and activation of several protective molecular pathways.
This has been demonstrated in endothelial cells and is likely to be
the case in other vascular cells such as monoctyes/macrophages. In
addition, HO-1 may be a protective gene against proatherogenic
effects caused by environmental factors such as cigarette smoking
or exposure to air pollution.
Basal HO-1 mRNA expression levels in response to injuri-
ous stimuli appear to be more important than the degree of
upregulation or fold induction for the protection against those
stimuli in the vasculature. In some circumstances, the levels
of HO-1 protein and HO functional activity may not be con-
cordant which could be due to posttranslational modifications.
Therefore, a better understanding of their kinetics in vascu-
lar processes such as atherosclerosis is required to shed light
on the reasons why very high levels of upregulated HO-1 in
vascular cells may be overwhelmed by the pathogenic process
and fail to abrogate the progression of atherosclerotic lesions.
Importantly, HO-1 can be targeted pharmacologically by inter-
ventions that seek its upregulation or enhancement of its var-
ious arms of action, via: (1) induction of HO-1 expression
with drugs such as heme arginate, (2) administration of CO
by inhalation or use of CO releasing molecules (CORM), and
(3) administration of biliverdin/bilirubin or use of inhibitors
of bilirubin conjugation that would result in increased bilirubin
levels.
One potential caveat, however, is that modulation of HO-1
could result in alteration of the activation status of its transcrip-
tion factor Nrf2, which has been shown to exert proatherosclerotic
effects. The discordant effects between Nrf2 and HO-1 under-
line the high degree of complexity that therapeutic modulation
of vascular oxidative stress must address. This is in addition to
studies that have shown that while some oxidation products pro-
mote inflammation in the vascular wall, others could have antiin-
flammatory activity instead. Indeed, electrophilic nitro-fatty acids
which are formed via nitric oxide or nitrite-dependent redox reac-
tions have been shown to exert antiinflammatory actions (Khoo
and Freeman, 2010). Therefore, any pharmacological modulation
of HO-1 should take into consideration any potential alteration of
the Nrf2 activation status.
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